Lysosomal acid lipase A and the hypercholesterolaemic phenotype

Current Opinion in Lipidology

Volumn 24, Issue 4, 2013, Pages 332-338

  Fouchier, Sigrid W ^a,b   Defesche, Joep C ^b  

^a Department of Vascular Medicine ^*  (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Cholesteryl ester storage disease; Lipase A; Lysosomal acid lipase; Monogenetic hypercholesterolaemia; Wolman disease

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ABC TRANSPORTER A1; ACID LIPASE; ADAPTOR PROTEIN; ALPHA TOCOPHEROL; ALPHA TOCOPHEROL DERIVATIVE; AMINOTRANSFERASE; APOLIPOPROTEIN B100; EZETIMIBE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR ADAPTOR PROTEIN 1; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LYSOSOMAL ACID LIPASE A; MEVINOLIN; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN LIKE KEXIN TYPE 9; PROTEIN PRECURSOR; SEBELIPASE ALFA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADD ON THERAPY; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; AUTOSOMAL RECESSIVE DISORDER; AUTOSOMAL RECESSIVE HYPERCHOLESTEROLEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL ESTER STORAGE DISEASE; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; DRUG EFFICACY; DRUG OXIDATION; ENZYME DEFICIENCY; ENZYME REPLACEMENT; EXOCYTOSIS; FAMILIAL DEFECTIVE APOLIPOPROTEIN B; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HYPERCHOLESTEROLEMIA; LIPID STORAGE; LIVER FUNCTION; LIVER SIZE; LYSOSOMAL ACID LIPASE A DEFICIENCY; LYSOSOME; METABOLIC REGULATION; NONHUMAN; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; WOLMAN DISEASE;

ANIMALS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PHENOTYPE; RISK FACTORS; STEROL ESTERASE;

ANIMALIA;

EID: 84880600716     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e328361f6c6     Document Type: Review

References (70)

1. Grabowski GA, Charnas L, Du H. Lysosomal Acid Lipase Deficiencies: The Wolman Disease/Cholesteryl Ester Storage Disease Spectrum. In: The Online Metabolic & Molecular Bases of Inherited Disease. Edited by Valle, Beaudet, Vogelstein, Kinzler, Antonarakis, Ballabio (Editors). Colombus, OH: McGraw-Hill; 2012. part 16, chapter 142. pp. 1-9.
2. Zhang B, Porto AF. Cholesteryl Ester Storage Disease: Protean Presentations of Lysosomal Acid Lipase Deficiency. J Pediatr Gastroenterol Nutr 2013.
3. Bernstein DL, Hulkova H, Bialer MG, et al. Cholesteryl Ester Storage Disease: Review of the Findings in 135 Reported Patients with an Under-Diagnosed Disease. J Hepatol 2013. pii: S0168-8278(13)00136-0. doi: 10.1016/j.jhep.2013. 02.014. [Epub ahead of print]
4. Brown MS, Hobbs HH, Goldstein JL. Familial Hypercholesterolemia. In: The Online Metabolic & Molecular Bases of Inherited Disease. Edited by Valle, Beaudet, Vogelstein, Kinzler, Antonarakis, Ballabio (Editors). Colombus, OH: McGraw-Hill; 2005. part 12, chapter 120. pp. 1-10.
5. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 2009; 50 (Suppl):S172-S177.
6. Garcia CK, Wilund K, Arca M, et al. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 2001; 292:1394-1398.
7. Austin MA, Hutter CM, Zimmern RL, et al. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol 2004; 160:407-420.
8. Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest 2003; 111: 1795-1803.
9. Scott SA, Liu B, Nazarenko I, et al. Frequency of the Cholesteryl ester storage disease common LIPA E8SJM mutation (c.894g>a) in various racial and ethnic groups. Hepatology 2013. doi: 10.1002/hep.26327. [Epub ahead of print]
10. Muntoni S, Wiebusch H, Jansen-Rust M, et al. Prevalence of cholesteryl ester storage disease. Arterioscler Thromb Vasc Biol 2007; 27:1866-1868.
11. Klima H, Ullrich K, Aslanidis C, et al. A splice junction mutation causes deletion of a 72-base exon from the mRNA for lysosomal acid lipase in a patient with cholesteryl ester storage disease. J Clin Invest 1993; 92:2713-2718.
12. Fasano T, Pisciotta L, Bocchi L, et al. Lysosomal lipase deficiency: molecular characterization of eleven patients with Wolman or cholesteryl ester storage disease. Mol Genet Metab 2012; 105:450-456.
13. Aslanidis C, Ries S, Fehringer P, et al. Genetic and biochemical evidence that CESD and Wolman disease are distinguished by residual lysosomal acid lipase activity. Genomics 1996; 33:85-93.
14. Goldstein JL, Dana SE, Faust JR, et al. Role of lysosomal acid lipase in the metabolism of plasma low density lipoprotein. Observations in cultured fibroblasts from a patient with cholesteryl ester storage disease. J Biol Chem 1975; 250:8487-8495.
15. Ginsberg HN, Le NA, Short MP, et al. Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis. J Clin Invest 1987; 80:1692-1697.
16. Cummings MH, Watts GF. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in cholesteryl ester storage disease. Clin Chem 1995; 41:111-114.
17. Levy R, Ostlund RE Jr, Schonfeld G, et al. Cholesteryl ester storage disease: complex molecular effects of chronic lovastatin therapy. J Lipid Res 1992; 33:1005-1015.
18. Ameis D, Brockmann G, Knoblich R, et al. A 5' splice-region mutation and a dinucleotide deletion in the lysosomal acid lipase gene in two patients with cholesteryl ester storage disease. J Lipid Res 1995; 36:241-250.
19. Muntoni S, Wiebusch H, Funke H, et al. Homozygosity for a splice junction mutation in exon 8 of the gene encoding lysosomal acid lipase in a Spanish kindred with cholesterol ester storage disease (CESD). Hum Genet 1995; 95:491-494.
20. Seedorf U, Wiebusch H, Muntoni S, et al. A novel variant of lysosomal acid lipase (Leu336->Pro) associated with acid lipase deficiency and cholesterol ester storage disease. Arterioscler Thromb Vasc Biol 1995; 15:773-778.
21. Gasche C, Aslanidis C, Kain R, et al. A novel variant of lysosomal acid lipase in cholesteryl ester storage disease associated with mild phenotype and improvement on lovastatin. J Hepatol 1997; 27:744-750.
22. Ries S, Buchler C, Schindler G, et al. Different missense mutations in histidine-108 of lysosomal acid lipase cause cholesteryl ester storage disease in unrelated compound heterozygous and hemizygous individuals. Hum Mutat 1998; 12:44-51.
23. Pisciotta L, Fresa R, Bellocchio A, et al. Cholesteryl Ester Storage Disease (CESD) due to novel mutations in the LIPA gene. Mol Genet Metab 2009; 97:143-148.
24. Anderson RA, Bryson GM, Parks JS. Lysosomal acid lipase mutations that determine phenotype in Wolman and cholesterol ester storage disease. Mol Genet Metab 1999; 68:333-345.
25. Lohse P, Maas S, Lohse P, et al. Compound heterozygosity for a Wolman mutation is frequent among patients with cholesteryl ester storage disease. J Lipid Res 2000; 41:23-31.
26. Elleder M, Chlumska A, Hyanek J, et al. Subclinical course of cholesteryl ester storage disease in an adult with hypercholesterolemia, accelerated atherosclerosis, and liver cancer. J Hepatol 2000; 32:528-534.
27. Hooper AJ, Tran HA, Formby MR, et al. A novel missense LIPA gene mutation, N98S, in a patient with cholesteryl ester storage disease. Clin Chim Acta 2008; 398:152-154.
28. Sauvage Nolting PR, Buirma RJ, Hutten BA, et al. Baseline lipid values partly determine the response to high-dose simvastatin in patients with familial hypercholesterolemia. The examination of probands and relatives in Statin studies with familial hypercholesterolemia (ExPRESS FH). Atherosclerosis 2002; 164:347-354.
29. Smilde TJ, Trip MD, Wollersheim H, et al. Rationale, design and baseline characteristics of a clinical trial comparing the effects of robust vs conventional cholesterol lowering and intima media thickness in patients with familial hypercholesterolaemia : The Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) Study. Clin Drug Investig 2000; 20:67-79.
30. Jansen AC, van Aalst-Cohen ES, Tanck MW, et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med 2004; 256:482-490.
31. van der Graaf A, Avis HJ, Kusters DM, et al. Molecular basis of autosomal dominant hypercholesterolemia: assessment in a large cohort of hypercholesterolemic children. Circulation 2011; 123:1167-1173.
32. Abifadel M, Guerin M, Benjannet S, et al. Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia. Atherosclerosis 2012; 223:394-400.
33. Lin J, Wang LY, Liu S, et al. A novel mutation in proprotein convertase subtilisin/kexin type 9 gene leads to familial hypercholesterolemia in a Chinese family. Chin Med J (Engl) 2010; 123:1133-1138.
34. Leren TP. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Clin Genet 2004; 65:419-422.
35. Ouguerram K, Chetiveaux M, Zair Y, et al. Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9. Arterioscler Thromb Vasc Biol 2004; 24:1448-1453.
36. Allard D, Amsellem S, Abifadel M, et al. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Hum Mutat 2005; 26:497.
37. Homer VM, Marais AD, Charlton F, et al. Identification and characterization of two nonsecreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa. Atherosclerosis 2008; 196:659-666.
38. Rodenburg J, Wiegman A, Vissers MN, et al. A boy with autosomal recessive hypercholesterolaemia. Neth J Med 2004; 62:89-93.
39. Zuliani G, Arca M, Signore A, et al. Characterization of a new form of inherited hypercholesterolemia: familial recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol 1999; 19:802-809.
40. Abera AB, Marais AD, Raal FJ, et al. Autosomal recessive hypercholesterolaemia: discrimination of ARH protein and LDLR function in the homozygous FH phenotype. Clin Chim Acta 2007; 378:33-37.
41. Quagliarini F, Vallve JC, Campagna F, et al. Autosomal recessive hypercholesterolemia in Spanish kindred due to a large deletion in the ARH gene. Mol Genet Metab 2007; 92:243-248.
42. Al-Kateb H, Bahring S, Hoffmann K, et al. Mutation in the ARH gene and a chromosome 13q locus influence cholesterol levels in a new form of digenicrecessive familial hypercholesterolemia. Circ Res 2002; 90:951-958.
43. Arca M, Zuliani G, Wilund K, et al. Autosomal recessive hypercholesterolaemia in Sardinia, Italy, and mutations in ARH: a clinical and molecular genetic analysis. Lancet 2002; 359:841-847.
44. Barbagallo CM, Emmanuele G, Cefalu AB, et al. Autosomal recessive hypercholesterolemia in a Sicilian kindred harboring the 432insA mutation of the ARH gene. Atherosclerosis 2003; 166:395-400.
45. Canizales-Quinteros S, Aguilar-Salinas CA, Huertas-Vazquez A, et al. A novel ARH splice site mutation in a Mexican kindred with autosomal recessive hypercholesterolemia. Hum Genet 2005; 116:114-120.
46. Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis 2012; 223:262-268.
47. Tarantino MD, McNamara DJ, Granstrom P, et al. Lovastatin therapy for cholesterol ester storage disease in two sisters. J Pediatr 1991; 118:131-135.
48. Iverson SA, Cairns SR, Ward CP, et al. Asymptomatic cholesteryl ester storage disease in an adult controlled with simvastatin. Ann Clin Biochem 1997; 34 (Pt 4):433-436.
49. vom DS, Harzer K, Rolfs A, et al. Hepatosplenomegalic lipidosis: what unless Gaucher? Adult cholesteryl ester storage disease (CESD) with anemia, mesenteric lipodystrophy, increased plasma chitotriosidase activity and a homozygous lysosomal acid lipase -1 exon 8 splice junction mutation. J Hepatol 1999; 31:741-746.
50. Elleder M, Chlumska A, Ledvinova J, et al. Testis: a novel storage site in human cholesteryl ester storage disease. Autopsy report of an adult case with a longstanding subclinical course complicated by accelerated atherosclerosis and liver carcinoma. Virchows Arch 2000; 436:82-87.
51. Chen W, Sun Y, Welch C, et al. Preferential ATP-binding cassette transporter A1-mediated cholesterol efflux from late endosomes/lysosomes. J Biol Chem 2001; 276:43564-43569.
52. Bowden KL, Bilbey NJ, Bilawchuk LM, et al. Lysosomal acid lipase deficiency impairs regulation of ABCA1 gene and formation of high density lipoproteins in cholesteryl ester storage disease. J Biol Chem 2011; 286:30624-30635.
53. Choi HY, Karten B, Chan T, et al. Impaired ABCA1-dependent lipid efflux and hypoalphalipoproteinemia in human Niemann-Pick type C disease. J Biol Chem 2003; 278:32569-32577.
54. Garver WS, Jelinek D, Meaney FJ, et al. The National Niemann-Pick Type C1 Disease Database: correlation of lipid profiles, mutations, and biochemical phenotypes. J Lipid Res 2010; 51:406-415.
55. Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012; 307:1302-1309.
56. Coronary Artery Disease (C4D) Genetics Consortium. A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. Nat Genet 2011; 43:339-344.
57. Wild PS, Zeller T, Schillert A, et al. A genome-wide association study identifies LIPA as a susceptibility gene for coronary artery disease. Circ Cardiovasc Genet 2011; 4:403-412.
58. IBC 50K CAD Consortium. Large-scale gene-centric analysis identifies novel variants for coronary artery disease. PLoS Genet 2011; 7:e1002260.
59. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008; 337:a2423.
60. Glueck CJ, Lichtenstein P, Tracy T, et al. Safety and efficacy of treatment of pediatric cholesteryl ester storage disease with lovastatin. Pediatr Res 1992; 32:559-565.
61. Rassoul F, Richter V, Lohse P, et al. Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease. Int J Clin Pharmacol Ther 2001; 39:199-204.
62. Leone L, Ippoliti PF, Antonicelli R. Use of simvastatin plus cholestyramine in the treatment of lysosomal acid lipase deficiency. J Pediatr 1991; 119:1008-1009.
63. McCoy E, Yokoyama S. Treatment of cholesteryl ester storage disease with combined cholestyramine and lovastatin. Ann N Y Acad Sci 1991; 623: 453-454.
64. Yokoyama S, McCoy E. Long-term treatment of a homozygous cholesteryl ester storage disease with combined cholestyramine and lovastatin. J Inherit Metab Dis 1992; 15:291-292.
65. Tadiboyina VT, Liu DM, Miskie BA, et al. Treatment of dyslipidemia with lovastatin and ezetimibe in an adolescent with cholesterol ester storage disease. Lipids Health Dis 2005; 4:26-31.
66. Xu M, Liu K, Swaroop M, et al. delta-Tocopherol reduces lipid accumulation in Niemann-Pick type C1 and Wolman cholesterol storage disorders. J Biol Chem 2012; 287:39349-39360.
67. Du H, Cameron TL, Garger SJ, et al. Wolman disease/cholesteryl ester storage disease: efficacy of plant-produced human lysosomal acid lipase in mice. J Lipid Res 2008; 49:1646-1657.
68. Leavitt M, Burt AD, Hu W, et al. Recombinant lysosomal acid lipase normalized liver weight, transaminases and histopathological abnormalities in an in vivo model of cholesterol storage ester disease [abstract]. J Hepatol 2011; 54 (Supplement 1):S358.
69. Leavitt M, Hu W, Canty D, et al. Efficacy of SBC-102, a recombinant enzyme replacement therapy, across a broad range of doses in an in vivo model of lysosomal acid lipase deficiency [abstract]. J Pediatr Gastroenterol Nutr 2011; 52 (Supplement 1):E20.
70. Balwani M, Breen C, Enns GM, et al. Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients with cholesteryl ester storage disease. Hepatology 2013. doi: 10.1002/hep.26289. [Epub ahead of print]